Ibrutinib: from bench side to clinical implications.
Milano, Italy. In Med Oncol, 30 Sep 2015
Thanks to the characterization and continuous discovery of the pathways driving B cell proliferation in consequence to BCR activation, it has been possible to develop a small molecule inhibitor specifically antagonizing the Bruton's tyrosine kinase (BTK), an enzyme located in an early strategic position within the whole pathway.
Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Rochester, United States. In Expert Rev Anticancer Ther, 21 Aug 2015
Here, we review novel therapeutic agents in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, which have emerged in the past decade and discuss their comparative efficacy and safety, with emphasis on a Bruton's tyrosine kinase (BTK) inhibitor, which has been recently approved by the US FDA, specifically for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
[Ibrutinib: A new drug of B-cell malignancies].
Paris, France. In Bull Cancer, 30 Jun 2015
Ibrutinib (Imbruvica(®)) is a first-in-class, orally administered once-daily, that inhibits B-cell antigen receptor signaling downstream of Bruton's tyrosine kinase (BTK).
B-cell receptor signaling in diffuse large B-cell lymphoma.
Bethesda, United States. In Semin Hematol, Apr 2015
Pharmacological inhibition with ibrutinib of Bruton's tyrosine kinase, a kinase that is required for BCR signaling to engage NF-κB, is selectively toxic for ABC DLBCL tumors; a finding that has now been translated to the clinic.
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ann Arbor, United States. In J Oncol Pharm Pract, Mar 2015
New therapies currently in the drug development pipeline for relapsed and refractory disease include additional proteasome inhibitors (oprozomib, marizomib, ixazomib), histone deacetylase inhibitors (panobinostat, ricolinostat, quisinostat), monoclonal antibodies (daratumumab, elotuzumab, SAR650984), Bruton's tyrosine kinase inhibitors (ibrutinib), a selective inhibitor of nuclear export, and others.